| Popis: |
Nicholas J. Razum, Albert B. Snyder, Daniel R. DoironPDT Pharmaceuticals, 7408 Hollister Avenue, Santa Barbara, CA 93 1 17 USAABSTRACT:Tin Ethyl Etiopurpurin, SIIET2, is a synthetic chiorin analog presently in Phase-Il/ill clinical trials for thetreatment of cutaneous cancers. Trials to date include the treatment of basal cell carcinomas, squamouscell carcinomas, breast adenocarcinomas metastatic to the chest wall and cutaneous Kaposi's sarcomas inAIDS patients. Results to date have shown significant clinical responses for drug doses between 1.Omgfkgand 1.6mg/kg, with the threshold for Kaposi's sarcoma being slightly higher than in other indications.Light doses from 100J/cm2 to 300J/cm2 were delivered from 24 to 72 hours post SrIET2 infusion. Inducedtransient skin photosensitivity at the lower therapeutic doses has been mild, lasting approximately a week.Results ofthe Phase I and II trials will be presented.Keywords: Photodynamic Therapy, PDT, Tin Ethyl Etiopurpurin, SnET2, cancer, Kaposi's sarcomaINTRODUCTION:With the recent FDA approval of Porfimer sodium (Photofrmn), Photodynamic Therapy is no longerstrictly an investigational therapy.' Second generation drugs are being tested clinically world-wide, withthird generation drugs soon to follow.2 New devices are continually being developed that greatly improvethe ease of patient treatment.3 These developments make this treatment accessible to an office-basedclinician, notjust large university-based medical centers.Photodynamic Therapy uses photoreactive drugs that concentrate preferentially in hyperproliferatingtissues, and are activated by low power non-thermal light to selectively destroy abnormal cells. Thisinteraction of light with drug results in the generation of singlet oxygen, a highly reactive oxidant that hasthe ability to react with lipids and proteins. This reaction results in cell necrosis.4 These photosensitizingdrugs may be systemically or locally, e.g. topically, administered. This paper will give an interim updateof ongoing clinical research using systemically infused SnET2.0819420492196/$6M0 |
